Products
Emfizatamab Biosimilar Tetraspecific Antibody (CD3 × CD19 × PD-L1 × 4-1BB) for Research
Cat No.: GMP-Bios-INN-1175
Anti-CD3E therapeutic antibody (Pre-made Emfizatamab biosimilar,Tetraspecific (scFv-IgG-scFv-scFv; Bispecific entry 1)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Emfizatamab (development code GNC-038) is a tetraspecific antibody targeting CD3, CD19, PD-L1 and 4-1BB. It is developed by Sichuan Baili Pharmaceutical for non-Hodgkin lymphoma. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1175-1mg | 1mg | |
| GMP-Bios-INN-1175-10mg | 10mg | |
| GMP-Bios-INN-1175-100mg | 100mg | |
| GMP-Bios-INN-1175-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Emfizatamab biosimilar, Tetraspecific (scFv-IgG-scFv-scFv; Bispecific entry 1), Anti-CD3E;CD19;PDL1/CD274;TNFRSF9/CD137/4-1BB Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
| INN Name | Emfizatamab |
| Target | CD3E;CD19;PDL1/CD274;TNFRSF9/CD137/4-1BB |
| Format | Tetraspecific (scFv-IgG-scFv-scFv; Bispecific entry 1) |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | na;G1 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | Sichuan Baili Pharmaceutical |
| Conditions Approved | na |
| Conditions Active | Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
